Skip to main content Accessibility help
×
Home
Hostname: page-component-55597f9d44-xbgml Total loading time: 0.272 Render date: 2022-08-12T03:59:17.345Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true } hasContentIssue true

Characteristics and Trend of Drug-Resistant Tuberculosis at a Major Specialized Hospital in Chongqing, China: 2016 Versus 2019

Published online by Cambridge University Press:  16 May 2022

Huizheng Zhang
Affiliation:
Central Laboratory, Chongqing Public Health Medical Center, Chongqing, China
Ke Zhang
Affiliation:
Department of Anesthesiology, Chongqing University Central Hospital, Chongqing, China School of Nursing, Southwest Medical University, Sichuan, China
Xin Yang
Affiliation:
Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Ming Luo
Affiliation:
Central Laboratory, Chongqing Public Health Medical Center, Chongqing, China
Chunhua Li
Affiliation:
Department of Radiology, Chongqing Public Health Medical Center, Chongqing, China
Xiaoying Wang*
Affiliation:
Faculty of Medical Technology, Chongqing Medical and Pharmaceutical College, Chongqing, China
Kui Hu*
Affiliation:
Department of Paediatrics, Dazhou Central Hospital, Sichuan, China
*
Corresponding authors: Xiaoying Wang, Email: diandiewxy@163.com; and Kui Hu, Email: 41593838@qq.com.
Corresponding authors: Xiaoying Wang, Email: diandiewxy@163.com; and Kui Hu, Email: 41593838@qq.com.

Abstract

Objective:

The epidemic of drug-resistant tuberculosis (DR-TB) has become a major concern in global TB control. This study aimed to investigate the patterns and trend of DR-TB epidemic between different time periods in Chongqing.

Methods:

A total of 985 and 835 culture positive TB patients with drug susceptibility testing (DST) results admitted to the hospital in 2016 and 2019, respectively, were included. Chi-square testing was used to compare the prevalence and trends of DR-TB in 2016 and 2019.

Results:

The proportion of previously treated TB cases with culture positivity was 45.7% in 2019, significantly higher than that in 2016 (39.1%, P = 0.004). The overall rate of drug resistance in 2019 was 43.1%, higher than that in 2016 (40.2%). The rates of multi-drug resistant TB (MDR-TB) and pre-extensively drug resistant TB (pre-XDR-TB) increased significantly from 2016 to 2019 among all TB cases (MDR: 25% vs 33.4%, P < 0.001 and pre-XDR: 7.1% vs 12.8%, P < 0.001, respectively) and previously treated TB cases (MDR: 46.5% vs 56%, P = 0.008 and pre-XDR: 13.2% vs 21.5%, P = 0.003, respectively).

Conclusions:

Our findings indicated that the prevalence of DR-TB remains high in Chongqing. The trend of resistance to anti-TB drugs beccame worse between 2016 and 2019. Moreover, acquired MDR may play a major role in MDR-TB epidemic in Chongqing. Therefore, rapid diagnosis and effective treatment of TB patients will be important to reduce the burden of DR-TB in Chongqing.

Type
Original Research
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of Society for Disaster Medicine and Public Health, Inc.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Global Tuberculosis Report 2020. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization. Published 2020. Accessed October 20, 2020. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf?sequence=1&isAllowed=y Google Scholar
Zhao, Y, Xu, S, Wang, L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366:2161-2170.CrossRefGoogle ScholarPubMed
Technical Guidance Group of the Fifth National TB Epidemiological Survey; The Office of the Fifth National TB Epidemiological Survey. The fifth national tuberculosis epidemiological survey in 2010. Chin J Antituberc. 2012;34(8):485-508.Google Scholar
Lan, Y, Li, Y, Chen, L, et al. Drug resistance profiles and trends in drug-resistant tuberculosis at a major hospital in Guizhou Province of China. Infect Drug Resist. 2019;12:211-219.CrossRefGoogle Scholar
Du, L, Zhang, Y, Lv, X, et al. Prevalence of multidrug-resistant tuberculosis in Dalian, China: a retrospective study. Infect Drug Resist. 2021;14:1037-1047.CrossRefGoogle ScholarPubMed
Song, WM, Li, YF, Ma, XB, et al. Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004-2018. Respir Res. 2019;20(1):223.CrossRefGoogle Scholar
An, Q, Song, W, Liu, J, et al. Primary drug-resistance pattern and trend in elderly tuberculosis patients in Shandong, China, from 2004 to 2019. Infect Drug Resist. 2020;13:4133-4145.CrossRefGoogle ScholarPubMed
Wu, B, Yu, Y, Du, C, et al. Epidemiology of drug-resistant tuberculosis in Chongqing, China: a retrospective observational study from 2010 to 2017. PLoS One. 2019;14:e0216018.CrossRefGoogle ScholarPubMed
Zhang, D, An, J, Wang, J, et al. Molecular typing and drug susceptibility of Mycobacterium tuberculosis isolates from Chongqing municipality, China. Infect Genet Evol. 2013;13:310-316.CrossRefGoogle ScholarPubMed
Laboratory Services in Tuberculosis Control. Part III: Culture. Geneva: World Health Organization. Published 1998. Accessed October 20, 2020. http://apps.who.int/iris/bitstream/handle/10665/65942/WHO_TB_98.258_(part3).pdf;jsessionid=64EF54513AD4144A520B24B4E3DFCBA5?sequence=3 Google Scholar
Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: World Health Organization. Published 2014. Accessed October 15, 2020. https://apps.who.int/iris/bitstream/handle/10665/130918/9789241548809_eng.pdf;jsessionid=D734B436EAD07048D194FF12306177F6?sequence=1 Google Scholar
Wang, L, Zhang, H, Ruan, Y, et al. Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data. Lancet. 2014;383:2057-2064.CrossRefGoogle ScholarPubMed
Davies, PD. The effects of poverty and ageing on the increase in tuberculosis. Monaldi Arch Chest Dis. 1999;54:168-171.Google ScholarPubMed
Tostmann, A, Kik, SV, Kalisvaart, NA, et al. Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis. 2008;47(9):1135-1142.CrossRefGoogle Scholar
WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment [M]. Geneva: World Health Organization. Published 2019. Accessed October 15, 2020. https://max.book118.com/html/2019/0411/8025124064002016.shtm Google Scholar
Pym, AS, Diacon, AH, Tang, SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47(2):564-574.CrossRefGoogle ScholarPubMed
Bloemberg, GV, Keller, PM, Stucki, D, et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med. 2015;373(20):1986-1988.CrossRefGoogle ScholarPubMed
Polsfuss, S, Hofmann-Thiel, S, Merker, M, et al. Emergence of low-level delamanid and bedaquiline resistance during extremely drug-resistant tuberculosis treatment. Clin Infect Dis. 2019;69(7):1229-1231.CrossRefGoogle ScholarPubMed
Ghodousi, A, Rizvi, AH, Baloch, AQ, et al. Acquisition of cross-resistance to bedaquiline and clofazimine following treatment for tuberculosis in Pakistan. Antimicrob Agents Chemother. 2019;63(9):e00915-e00919.CrossRefGoogle ScholarPubMed
Nimmo, C, Millard, J, van Dorp, L, et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe. 2020;1(4):e165-e174.CrossRefGoogle ScholarPubMed
Liu, Y, Gao, J, Du, J, et al. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. Int J Infect Dis. 2021;102:392-396.CrossRefGoogle ScholarPubMed
Li, D, Wang, JL, Ji, BY, et al. Persistently high prevalence of primary resistance and multidrug resistance of tuberculosis in Heilongjiang Province, China. BMC Infect Dis. 2016;16:516.CrossRefGoogle ScholarPubMed
He, XC, Zhang, XX, Zhao, JN, et al. Epidemiological trends of drug-resistant tuberculosis in China from 2007 to 2014. Medicine. 2016;95:1-7.CrossRefGoogle ScholarPubMed
Hu, Y, Xu, L, He, YL, et al. Prevalence and molecular characterization of second-line drugs resistance among multidrug-resistant Mycobacterium tuberculosis isolates in southwest of China. Biomed Res Int. 2017; Epub 2017 Jul 17. doi: 10.1155/2017/4563826 CrossRefGoogle ScholarPubMed
Nsofor, CA, Jiang, Q, Wu, J, et al. Transmission is a noticeable cause of resistance among treated tuberculosis patients in Shanghai, China. Sci Rep. 2017;7:7691.CrossRefGoogle ScholarPubMed
Gao, Q, Mei, J. Transmission is the main cause of high rate of drug-resistant tuberculosis in China. Chin J Antituberc. 2015;37:1091-1096.Google Scholar
Peng, Y, Chen, SH, Zhang, L, et al. Multidrug-resistant tuberculosis burden among the new tuberculosis patients in Zhejiang Province: an observational study, 2009-2013. Chin Med J (Engl). 2017;130:2021-2026.CrossRefGoogle ScholarPubMed
Yang, C, Shen, X, Peng, Y, et al. Transmission of Mycobacterium tuberculosis in China: a population-based molecular epidemiologic study. Clin Infect Dis. 2015;61:219-227.CrossRefGoogle ScholarPubMed
Driessche, KV, Mahlobo, PZ, Venter, R, et al. Face masks in the post-COVID-19 era: a silver lining for the damaged tuberculosis public health response? Lancet Respir Med. 2021;9(4):340-342.CrossRefGoogle Scholar
Siddiqi, K, Lambert, M-L, Walley, J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis. 2003;3:288-296.CrossRefGoogle ScholarPubMed
WHA Approves Post-2015 Global TB Strategy and Targets. Geneva: World Health Organization. Published 2014. Accessed November 14, 2020. http://who.int/tb/features_archive/globaltb_strategy/en/ Google Scholar

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Characteristics and Trend of Drug-Resistant Tuberculosis at a Major Specialized Hospital in Chongqing, China: 2016 Versus 2019
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Characteristics and Trend of Drug-Resistant Tuberculosis at a Major Specialized Hospital in Chongqing, China: 2016 Versus 2019
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Characteristics and Trend of Drug-Resistant Tuberculosis at a Major Specialized Hospital in Chongqing, China: 2016 Versus 2019
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *